【联康生物科技集团(00690.HK):眼科药物金因康®获批上市】联康生物科技集团(00690.HK)公布,中国国家药品监督管理局(NMPA)已于2025年5月21日批准集团的眼科新产品金因康®(地夸磷索钠滴眼液)的上市申请,批准文号为“国药准字H20254149”。金因康®的获批标志着集团眼科药物管线的进一步完善,为干眼症患者提供更加多样化的治疗方案。

金融界
21 May
联康生物科技集团(00690.HK)公布,中国国家药品监督管理局(NMPA)已于2025年5月21日批准集团的眼科新产品金因康®(地夸磷索钠滴眼液)的上市申请,批准文号为“国药准字H20254149”。金因康®的获批标志着集团眼科药物管线的进一步完善,为干眼症患者提供更加多样化的治疗方案。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10